Genes proximal and distal to MYCN are highly expressed in human neuroblastoma as visualized by comparative expressed sequence hybridization

American Journal of Pathology

Volumn 172, Issue 1, 2008, Pages 203-214

  Stock, Cornelia ^a   Bozsaky, Eva ^a   Watzinger, Franz ^a   Poetschger, Ulrike ^a   Orel, Lukas ^a   Lion, Thomas ^a   Kowalska, Agata ^a   Ambros, Peter F ^a,b  

^a CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^b ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

RNA;

ALK GENE; AMPLICON; ARTICLE; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; MYCN GENE; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 38749140993     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2008.061263     Document Type: Article

References (56)

1. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985, 313:1111-1116
2. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984, 224:1121-1124
3. Akiyama K, Kanda N, Yamada M, Tadokoro K, Matsunaga T, Nishi Y: Megabase-scale analysis of the origin of N-myc amplicons in human neuroblastomas. Nucleic Acids Res 1994, 22:187-193
4. Beheshti B, Braude I, Marrano P, Thorner P, Zielenska M, Squire JA: Chromosomal localization of DNA amplifications in neuroblastoma tumors using cDNA microarray comparative genomic hybridization. Neoplasia 2003, 5:53-62
5. Lastowska M, Viprey V, Santibanez-Koref M, Wappler I, Peters H, Cullinane C, Roberts P, Hall AG, Tweddle DA, Pearson ADJ, Lewis I, Burchill SA, Jackson MS: Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data. Oncogene 2007, 26:7432-7444
6. De Preter K, Speleman F, Combaret V, Lunec J, Board J, Pearson A, De Paepe A, Van Roy N, Laureys G, Vandesompele J: No evidence for correlation of DDX1 gene amplification with improved survival probability in patients with MYCN-amplified neuroblastomas. J Clin Oncol 2005, 23:3167-3170
7. George RE, Kenyon R, McGuckin AG, Kohl N, Kogner P, Christiansen H, Pearson ADJ, Lunec J: Analysis of candidate gene co-amplification with MYCN in neuroblastoma. Eur J Cancer 1997, 33:2037-2042
8. Kaneko S, Ohira M, Nakamura Y, Isogai E, Nakagawara A, Kaneko M: Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma. J Cancer Res Clin Oncol 2007, 133:185-192
9. Squire JA, Thorner PS, Weitzman S, Maggi JD, Dirks P, Doyle J, Hale M, Godbout R: Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma. Oncogene 1995, 10:1417-1422
10. Weber A, Imisch P, Bergmann E, Christiansen H: Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma. J Clin Oncol 2004, 22:2681-2690
11. Lasorella A, Boldrini R, Dominici C, Donfrancesco A, Yokota Y, Inserra A, Iavarone A: Id2 is critical for cellular proliferation and is the oncogenic effector of N-myc in human neuroblastoma. Cancer Res 2002, 62:301-306
12. Vandesompele J, Edsjo A, De Preter K, Axelson H, Speleman F, Pahlman S: ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value. Oncogene 2003, 22:456-460
13. Gebauer S, Yu AL, Omura-Minamisawa M, Batova A, Diccianni MB: Expression profiles and clinical relationships of ID2. CDKN1B, and CDKN2A in primary neuroblastoma. Genes Chromosomes Cancer 2004, 41:297-308
14. Chen QR, Bilke S, Wei JS, Whiteford CC, Cenacchi N, Krasnoselsky AL, Greer BT, Son CG, Westermann F, Berthold F, Schwab M, Catchpoole D, Khan J: cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma. BMC Genomics 2004, 5:70
15. De Preter K, Pattyn F, Berx G, Strumane K, Menten B, Van Roy F, De Paepe A, Speleman F, Vandesompele J: Combined subtractive cDNA cloning and array CGH: an efficient approach for identification of overexpressed genes in DNA amplicons. BMC Genomics 2004, 5:11
16. Scott DK, Board JR, Lu X, Pearson ADJ, Kenyon RM, Lunec J: The neuroblastoma amplified gene. NAG: genomic structure and characterisation of the 73 kb transcript predominantly expressed in neuroblastoma. Gene 2003, 307:1-11
17. Osajima-Hakomori Y, Miyake I, Ohira M, Nakagawara A, Nakagawa A, Sakai R: Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol 2005, 167:213-222
18. Michels E, Vandesompele J, Hoebeeck J, Menten B, De Preter K, Laureys G, Van Roy N, Speleman F: Genome wide measurement of DNA copy number changes in neuroblastoma: dissecting amplicons and mapping losses, gains and breakpoints. Cytogenet Genome Res 2006, 115:273-282
19. Mosse YP, Greshock J, Weber BL, Maris JM: Measurement and relevance of neuroblastoma DNA copy number changes in the postgenome era. Cancer Lett 2005, 228:83-90
20. De Preter K, Vandesompele J, Heimann P, Yigit N, Beckman S, Schramm A, Eggert A, Stallings R, Benoit Y, Renard M, Paepe A, Laureys G, Pahlman S, Speleman F: Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. Genome Biology 2006, 7:R84
21. Schramm A, Schulte JH, Klein-Hitpass L, Havers W, Sieverts H, Berwanger B, Christiansen H, Warnat P, Brors B, Eils J, Eils R, Eggert A: Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene 2005, 24:7902-7912
22. Schulte JH, Schramm A, Klein-Hitpass L, Klenk M, Wessels H, Hauffa BP, Eils J, Eils R, Brodeur GM, Schweigerer L, Havers W, Eggert A: Microarray analysis reveals differential gene expression patterns and regulation of single target genes contributing to the opposing phenotype of TrkA- and TrkB-expressing neuroblastomas. Oncogene 2005, 24:165-177
23. Takita J, Ishii M, Tsutsumi S, Tanaka Y, Kato K, Toyoda Y, Hanada R, Yamamoto K, Hayashi Y, Aburatani H: Gene expression profiling and identification of novel prognostic marker genes in neuroblastoma. Genes Chromosomes Cancer 2004, 40:120-132
24. Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG, Chen QR, Whiteford CC, Bilke S, Krasnoselsky AL, Cenacchi N, Catchpoole D, Berthold F, Schwab M, Khan J: Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 2004, 64:6883-6891
25. Mosse YP, Greshock J, Margolin A, Naylor T, Cole K, Khazi D, Hii G, Winter C, Shahzad S, Asziz MU, Biegel JA, Weber BL, Maris JM: High-resolution detection and mapping of genomic DNA alterations in neuroblastoma. Genes Chromosomes Cancer 2005, 43:390-403
26. Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, Seiser E, Jagannathan J, Shusterman S, Bansal M, Khazi D, Winter C, Okawa E, Grant G, Cnaan A, Zhao H, Cheung N-K, Gerald W, London W, Matthay KK, Brodeur GM, Maris JM: Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 2006, 62:6050-6062
27. Gentleman R, Carey V, Huber W; Irizarry R, Dudoit S: Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Statistics for Biology and Health 2005, 19:1-473 Springer, 2005
28. Lu YJ, Williamson D, Clark J, Wang R, Tiffin N, Skelton L, Gordon T, Williams R, Allan B, Jackman A, Cooper C, Pritchard-Jones K, Shipley J: Comparative expressed sequence hybridization to chromosomes for tumor classification and identification of genomic regions of differential gene expression. Proc Natl Acad Sci USA 2001, 98:9197-9202
29. Bentz M, Plesch A, Stilgenbauer S, Dohner H, Lichter P: Minimal sizes of deletions detected by comparative genomic hybridization. Genes Chromosomes Cancer 1998, 21:172-175
30. Joos S, Scherthan H, Speicher MR, Schlegel J, Cremer T, Lichter P: Detection of amplified DNA sequences by reverse chromosome painting using genomic tumor DNA as probe. Hum Genet 1993, 90:584-589
31. Piper J, Rutovitz D, Sudar D, Kallioniemi A, Kallioniemi OP, Waldman FM, Gray JW, Pinkel D: Computer image analysis of comparative genomic hybridization. Cytometry 1995, 19:10-26
32. Parente F, Gaudray P, Carle GF, Turc-Carel C: Experimental assessment of the detection limit of genomic amplification by comparative genomic hybridization CGH. Cytogenet Cell Genet 1997, 78:65-68
33. Kirchhoff M, Gerdes T, Maahr J, Rose H, Bentz M, Dohner H, Lundsteen C: Deletions below 10 megabasepairs are detected in comparative genomic hybridization by standard reference intervals. Genes Chromosomes Cancer 1999, 25:410-413
34. Lu YJ, Williamson D, Wang R, Summersgill B, Rodriguez S, Rogers S, Pritchard-Jones K, Campbell C, Shipley J: Expression profiling targeting chromosomes for tumor classification and prediction of clinical behavior. Genes Chromosomes Cancer 2003, 38:207-214
35. Vanden Bempt I, Vanhentenrijk V, Drijkoningen M, Wolf-Peeters CD: Comparative expressed sequence hybridization reveals differential gene expression in morphological breast cancer subtypes. J Pathol 2006, 208:486-494
36. Lu YJ, Hing S, Williams R, Pinkerton R, Shipley J, Pritchard-Jones K: Chromosome 1q expression profiling and relapse in Wilms' tumour. Lancet 2002, 360:385-386
37. Ambros IM, Rumpler S, Luegmayr A, Hattinger CM, Strehl S, Kovar H, Gadner H, Ambros PF: Neuroblastoma cells can actively eliminate supernumerary MYCN gene copies by micronucleus formation: sign of tumour cell revertance? Eur J Cancer 1997, 33:2043-2049
38. Narath R, Ambros IM, Kowalska A, Bozsaky E, Boukamp P, Ambros PF: Induction of senescence in MYCN amplified neuroblastoma cell lines by hydroxyurea. Genes Chromosomes Cancer 2006
39. Hattinger CM, Rumpler S, Strehl S, Ambros IM, Zoubek A, Potschger U, Gadner H, Ambros PF: Prognostic impact of deletions at 1p36 and numerical aberrations in Ewing tumors. Genes Chromosomes Cancer 1999, 24:243-254
40. Stock C, Kager L, Fink FM, Gadner H, Ambros PF: Chromosomal regions involved in the pathogenesis of osteosarcomas. Genes Chromosomes Cancer 2000, 28:329-336
41. Stock C, Ambros IM, Lion T, Zoubek A, Amann G, Gadner H, Ambros PF: Genetic changes of two Wilms tumors with anaplasia and a review of the literature suggesting a marker profile for therapy resistance. Cancer Genet Cytogenet 2002, 135:128-138
42. Stock C, Ambros IM, Lion T, Haas OA, Zoubek A, Gadner H, Ambros PF: Detection of numerical and structural chromosome abnormalities in pediatric germ cell tumors by means of interphase cytogenetics. Genes Chromosomes Cancer 1994, 11:40-50
43. Kallioniemi OP, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW, Pinkel D: Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 1994, 10:231-243
44. Bordow SB, Norris MD, Haber PS, Marshall GM, Haber M: Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. J Clin Oncol 1998, 16:3286-3294
45. Chan HL, Gallie BL, DeBoer G, Haddad G, Ikegaki N, Dimitroulakos J, Yeger H, Ling V: MYCN protein expression as a predictor of neuroblastoma prognosis. Clin Cancer Res 1997, 3:1699-1706
46. Cohn SL, London WB, Huang D, Katzenstein HM, Salwen HR, Reinhart T, Madafiglio J, Marshall GM, Norris MD, Haber M: MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol 2000, 18:3604-3613
47. Hiyama E, Hiyama K, Yokoyama T, Ishii T: Immunohistochemical analysis of N-myc protein expression in neuroblastoma: correlation with prognosis of patients. J Pediatr Surg 1991, 26:838-843
48. Tang XX, Zhao H, Kung B, Kim DY, Hicks SL, Cohn SL, Cheung N-K, Seeger RC, Evans AE, Ikegaki N: The MYCN enigma: significance of MYCN expression in neuroblastoma. Cancer Res 2006, 66:2826-2833
49. Alaminos M, Mora J, Cheung N-KV, Smith A, Qin J, Chen L, Gerald WL: Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma. Cancer Res 2003, 63:4538-4546
50. Matsunaga T, Shirasawa H, Hishiki T, Yoshida H, Kouchi K, Ohtsuka Y, Kawamura K, Etoh T, Ohnuma N: Enhanced expression of N-myc messenger RNA in neuroblastomas found by mass screening. Clin Cancer Res 2000, 6:3199-3204
51. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, Kidd VJ: Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000, 6:529-535
52. Ambros PF, Ambros IM: Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol 2001, 37:492-504
53. Stallings RL, Nair P, Maris JM, Catchpoole D, McDermott M, O'Meara A, Breatnach F: High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. Cancer Res 2006, 66:3673-3680
54. Lamant L, Pulford K, Bischof D, Morris SW, Mason DY, Delsol G, Mariame B: Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 2000, 156:1711-1721
55. Miyake I, Hakomori Y, Shinohara A, Gamou T, Saito M, Iwamatsu A, Sakai R: Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene 2002, 21:5823-5834
56. George RE, Attiyeh EF, Li S, Moreau LA, Neuberg D, Li C, Fox EA, Meyerson M, Diller L, Fortina P, Look AT, Maris JM: Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS ONE 2007, 2:e255